 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF, which is focused on the development of treatments for mental disorders, revealed that it is working with its collaborators on a key research publication on its LSD-derivative molecule BETR-001, and plans to submit it to a prestigious peer-review journal for assessment and critique by the end of September this year. The Vancouver, British Columbia-based biotech said that the publication will present data from a comprehensive preclinical in-vitro and in-vivo characterization of BETR-001, its proprietary 2-bromo-LSD, conducted in collaboration with three leading investigators in the field: Dr Adam L Halberstadt from the University of California San Diego, Dr Argel Aguilar-Valles from the Carleton University in Canada, and Dr John D McCorvy from the Medical College of Wisconsin in the United States. 